J. Molner AS Announces Approval and Upcoming Market Launch of Desoximetasone Ointment USP, 0.05% Tallinn, 2024-12-04 10:10 CET --
J. Molner AS (Nasdaq Tallinn: MOLNR) is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental application to its approved ANDA for Desoximetasone Ointment USP, 0.05% to support its change to a new manufacturing site.
This FDA supplement approval enables J. Molner AS to manufacture and market Desoximetasone Ointment USP, 0.05% in the U.S. market.
Desoximetasone Ointment USP, 0.05% is a potent corticosteroid medication used for the relief of inflammation and itching associated with various skin conditions, including eczema, psoriasis, and allergic dermatitis. It works by reducing swelling, redness, and discomfort in affected areas, offering effective treatment for moderate to severe dermatoses that respond to topical corticosteroids.
The company plans to commence the sale of this medication in the United States in January 2025. The market launch of this product will strengthen J. Molner AS's position as a provider of high-quality, affordable medicines and support the company’s growth in the U.S. market.
For additional information about J. Molner AS, please visit www.jmolner.com.
For additional information please contact:
Sten Akel
J. Molner AS
CFO
+372 550 5259
s.akel@jmolner.com
|